A Review on Steroidal 5-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

E-ISSN： 1875-533x|18|23|3576-3589

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.23, 2011-08, pp. : 3576-3589

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of 5-Reductase in the Treatment of Benign Prostatic Hyperplasia

Current Pharmaceutical Design, Vol. 12, Iss. 7, 2006-03 ,pp. : 775-783

Bentham Science Publishers

Access to resources Recommend Favorite

Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

By Djavan Bob Milani Shirin Fong Yan Kit

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

Comparison of α-Blocker Monotherapy and α-Blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia

By Joo K-J Sung W-S Park S-H Yang W-J Kim T-H

The Journal of International Medical Research, Vol. 40, Iss. 3, 2012-05 ,pp. : 899-908

Field House Publishing

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher Kapoor Anil

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite